HTA

💰 Is pembrolizumab delivering high value for HNSCC in Switzerland? A new analysis confirms the immunotherapy offers strong cost-effectiveness, supporting smarter resource allocation and improved patient outcomes in oncology. Explore the full economic evaluation and its implications for market access. #SyenzaNews #oncology #HealthEconomics #costeffectiveness #MarketAccess

Is tirzepatide delivering better value than semaglutide for patients and payers? A fresh analysis shows how tirzepatide can drive greater cost savings alongside improved health outcomes in obesity and type 2 diabetes management. Discover the key findings shaping treatment and reimbursement decisions. #SyenzaNews #pharmaceuticals #HealthEconomics #costeffectiveness

❓ How is Portugal’s approval of ublituximab reshaping access to multiple sclerosis therapies? The decision introduces new restrictions that could limit patient options and complicate market entry for innovative MS treatments. Explore the full implications for healthcare access and regulatory strategy. #SyenzaNews #pharmaceuticals #HealthcareInnovation #MarketAccess #healthcarepolicy

Portugal's INFARMED has blocked public funding for Datroway in breast cancer, citing insufficient added value.

How is South Africa advancing local production of cutting-edge HIV treatments? The country has shortlisted manufacturers for Lenacapavir, paving the way for greater domestic capacity, improved access, and stronger pharmaceutical supply chains across the region. Explore how this step supports broader drug development goals. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

Is integrated care in Canada losing momentum? Walter Wodchis’ blueprint outlines a practical path to coordinated, patient-centered services, yet progress has stalled amid structural and policy barriers. This analysis explores the key challenges and what’s needed to move forward. Read the full breakdown to see how Canada can get integrated care back on track. #SyenzaNews #HealthcareInnovation #healthcare #innovation #healthcarepolicy

Is the Dutch health insurance fund heading back into the red? Projections show the Zorgverzekeringsfonds returning to an operating deficit in 2026, raising fresh questions about long-term sustainability and the balance between premiums, benefits, and public spending. Read the full analysis to see what this means for healthcare financing. #SyenzaNews #healthcare #HealthEconomics #MarketAccess #healthcarepolicy

How is Portugal expanding access to advanced prostate cancer therapies? The country has approved reimbursement for the niraparib-abiraterone combination, strengthening patient options in oncology and highlighting progress in pharmaceutical market access. Discover what this means for treatment innovation and healthcare policy. #SyenzaNews #oncology #MarketAccess

What happens when Medicare Part D subsidies end? Beneficiaries could see modest premium increases next year as federal support phases out, potentially shifting more costs to seniors and affecting prescription drug affordability across the U.S. Explore the latest analysis on these changes and their market implications. #SyenzaNews #healthcare #HealthEconomics #healthcarepolicy #costeffectiveness

🚀 What if room-temperature plasma could redefine remote patient care? The FDA has granted approval for this innovative technology, enabling safe, effective treatments beyond traditional clinical settings and expanding access for patients worldwide. Discover how this breakthrough is shaping the future of decentralized healthcare. #SyenzaNews #MedTech #HealthcareInnovation #innovation #DigitalTransformation

🌍 Are Portugal’s children facing unequal health opportunities based on where they live? A new national survey reveals significant regional gaps in child health outcomes, highlighting disparities in access, prevention, and care that demand targeted policy action. Read the full analysis to see what these findings mean for equitable health strategies. #SyenzaNews #globalhealth #HealthEconomics #healthcarepolicy #economicanalysis

What does the FDA’s approval of ophthalmic bevacizumab mean for wet AMD patients? The agency has cleared a dedicated ophthalmic formulation, offering clinicians a targeted, cost-effective option to slow vision loss in one of the leading causes of blindness. Discover how this decision could reshape treatment pathways and market dynamics. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess